Share：
Share this content in WeChat
X
[Chinese][PDF]3733
• Clinical Article •
Diagnostic value of native T1 and ECV in myocardial amyloidosis: A Meta-analysis
WANG Guohui  MENG Li  BAO Haihua  LI Wenxin 

Cite this article as: WANG G H, MENG L, BAO H H, et al. Diagnostic value of native T1 and ECV in myocardial amyloidosis: A Meta-analysis[J]. Chin J Magn Reson Imaging, 2024, 15(3): 81-85, 92. DOI:10.12015/issn.1674-8034.2024.03.014.


[Abstract] Objective The Meta-analysis was used to explore the diagnostic value of native T1 and extracellular volume fraction (ECV) for cardiac amyloidosis (CA).Materials and Methods PubMed, Embase, Cochrane Library, Web of Science, Wanfang Database, CBM, VIP and CNKI were searched to explore the value of T1 and ECV of the diagnostic value in CA. The search time was from the establishment of the database to November 2022. Two researchers independently completed the literature screening, extracted the relevant data included in the literature and evaluated the quality. The bias risk was evaluated and statistically analyzed by Revman 5.3, Stata 16.0 and Meta-Disc 1.4. Heterogeneity and publication bias analysis were carried out. Sensitivity analysis was used to verify the stability and reliability of Meta-analysis results.Results A total of 12 articles (1 045 patients) were included. Meta-analysis showed that sensitivity (Sen), specificity (Spe), positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), area under the curve (AUC) and 95% confidence interval (CI) of T1 diagnostic CA were 86% (95% CI: 82%-89%), 86% (95% CI: 80%-91%), 6.2 (95% CI: 4.2-9.3), 0.16 (95% CI: 0.12-0.22), 38 (95% CI: 19-75), 0.92 (95% CI: 0.90-0.94). The Sen, Spe, PLR, NLR, DOR, and AUC of ECV diagnostic CA were 90% (95% CI: 83%-94%), 90% (95% CI: 83%-94%), 8.8 (95% CI: 5.3-14.6), 0.11 (95% CI: 0.07-0.19), 79 (95% CI: 38-162), and 0.95 (95% CI: 0.93-0.97).Conclusions Native T1 value and ECV have high diagnostic value for CA and can provide imaging basis for the early diagnosis of CA.
[Keywords] cardiac amyloidosis；cardiac magnetic resonance；T1 mapping；extracellular volume fraction；Meta-analysis

WANG Guohui1   MENG Li1*   BAO Haihua1   LI Wenxin2  

1 Medical Imaging Center, Qinghai University Affiliated Hospital, Xining 810001, China

2 Department of Ultrasound Medicine, Qinghai University Affiliated Hospital, Xining 810001, China

Corresponding author: MENG L, E-mail: qh_mengli@126.com

Conflicts of interest   None.

Received  2023-05-30
Accepted  2024-02-23
DOI: 10.12015/issn.1674-8034.2024.03.014
Cite this article as: WANG G H, MENG L, BAO H H, et al. Diagnostic value of native T1 and ECV in myocardial amyloidosis: A Meta-analysis[J]. Chin J Magn Reson Imaging, 2024, 15(3): 81-85, 92. DOI:10.12015/issn.1674-8034.2024.03.014.

[1]
JOURY A, GUPTA T, KRIM S R. Cardiac amyloidosis: presentations, diagnostic work-up and collaborative approach for comprehensive clinical management[J/OL]. Curr Probl Cardiol, 2021, 46(10): 100910 [2023-05-29]. https://pubmed.ncbi.nlm.nih.gov/34175153/. DOI: 10.1016/j.cpcardiol.2021.100910.
[2]
MARTINEZ-NAHARRO A, BAKSI A J, HAWKINS P N, et al. Diagnostic imaging of cardiac amyloidosis[J]. Nat Rev Cardiol, 2020, 17(7): 413-426. DOI: 10.1038/s41569-020-0334-7.
[3]
GERTZ M A, DISPENZIERI A. Systemic amyloidosis recognition, prognosis, and therapy: a systematic review[J]. JAMA, 2020, 324(1): 79-89. DOI: 10.1001/jama.2020.5493.
[4]
DORBALA S, CUDDY S, FALK R H. How to image cardiac amyloidosis: a practical approach[J]. JACC Cardiovasc Imaging, 2020, 13(6): 1368-1383. DOI: 10.1016/j.jcmg.2019.07.015.
[5]
RUBIN J, MAURER M S. Cardiac amyloidosis: overlooked, underappreciated, and treatable[J/OL]. Annu Rev Med, 2020, 71: 203-219 [2023-05-29]. https://pubmed.ncbi.nlm.nih.gov/31986086/. DOI: 10.1146/annurev-med-052918-020140.
[6]
HOTTA V T, GIORGI M C P, FERNANDES F, et al. Cardiac amyloidosis: non-invasive diagnosis[J]. Rev Assoc Med Bras (1992), 2020, 66(3): 345-352. DOI: 10.1590/1806-9282.66.3.345.
[7]
GARCIA-PAVIA P, RAPEZZI C, ADLER Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases[J]. Eur Heart J, 2021, 42(16): 1554-1568. DOI: 10.1093/eurheartj/ehab072.
[8]
TANG Z H, LIU J, ZHANG X, et al. Research progress of cardiovascular magnetic resonance imaging for the evaluation of cardiac amyloidosis[J]. Int J Med Radiol, 2022, 45(3): 307-312. DOI: 10.19300/j.2022.Z19671.
[9]
JURCUŢ R, ONCIUL S, ADAM R, et al. Multimodality imaging in cardiac amyloidosis: a primer for cardiologists[J]. Eur Heart J Cardiovasc Imaging, 2020, 21(8): 833-844. DOI: 10.1093/ehjci/jeaa063.
[10]
HUANG P N, DENG Y B. Research progresses of echocardiography for diagnosing cardiac amyloidosis and prognosis evaluation[J]. Chin J Med Imag Technol, 2022, 38(2): 304-307. DOI: 10.13929/j.issn.1003-3289.2022.02.034.
[11]
RAN L P, HUANG L, ZHAO P J, et al. Assessment of left ventricular hypertrophy using non-contrast T1mapping[J]. Chin J Radiol, 2018, 52(5): 374-378. DOI: 10.3760/cma.j.issn.1005-1201.2018.05.010.
[12]
BAGGIANO A, BOLDRINI M, MARTINEZ-NAHARRO A, et al. Noncontrast magnetic resonance for the diagnosis of cardiac amyloidosis[J]. JACC Cardiovasc Imaging, 2020, 13(1 Pt 1): 69-80. DOI: 10.1016/j.jcmg.2019.03.026.
[13]
MESSROGHLI D R, MOON J C, FERREIRA V M, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI)[J/OL]. J Cardiovasc Magn Reson, 2017, 19(1): 75 [2023-05-29]. https://pubmed.ncbi.nlm.nih.gov/28992817/. DOI: 10.1186/s12968-017-0389-8.
[14]
WANG T K M, BRIZNEDA M V, KWON D H, et al. Reference ranges, diagnostic and prognostic utility of native T1 mapping and extracellular volume for cardiac amyloidosis: a meta-analysis[J]. J Magn Reson Imaging, 2021, 53(5): 1458-1468. DOI: 10.1002/jmri.27459.
[15]
LIU Y M, ZHU J F, CHEN M, et al. 3.0T cardiac magnetic resonance quantification of native T1 and myocardial extracellular volume for the diagnosis of late gadolinium enhancement-negative cardiac amyloidosis[J/OL]. Ann Transl Med, 2022, 10(14): 794 [2023-05-29]. https://pubmed.ncbi.nlm.nih.gov/35965812/. DOI: 10.21037/atm-22-3251.
[16]
NAM B D, KIM S M, JUNG H N, et al. Comparison of quantitative imaging parameters using cardiovascular magnetic resonance between cardiac amyloidosis and hypertrophic cardiomyopathy: inversion time scout versus T1 mapping[J]. Int J Cardiovasc Imaging, 2018, 34(11): 1769-1777. DOI: 10.1007/s10554-018-1385-2.
[17]
QU Y J, YANG Z R, SUN F, et al. Risk on bias assessment: (6) A Revised Tool for the Quality Assessment on Diagnostic Accuracy Studies (QUADAS-2)[J]. Zhonghua Liu Xing Bing Xue Za Zhi, 2018, 39(4): 524-531. DOI: 10.3760/cma.j.issn.0254-6450.2018.04.028.
[18]
AQUARO G D, PUGLIESE N R, PERFETTO F, et al. Myocardial signal intensity decay after gadolinium injection: a fast and effective method for the diagnosis of cardiac amyloidosis[J]. Int J Cardiovasc Imag, 2014, 30(6): 1105-1115. DOI: 10.1007/s10554-014-0436-6.
[19]
BARISON A, AQUARO G D, PUGLIESE N R, et al. Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging[J]. J Intern Med, 2015, 277(5): 605-614. DOI: 10.1111/joim.12324.
[20]
FONTANA M, BANYPERSAD S M, TREIBEL T A, et al. Native T1 mapping in transthyretin amyloidosis[J]. JACC Cardiovasc Imaging, 2014, 7(2): 157-165. DOI: 10.1016/j.jcmg.2013.10.008.
[21]
GALLEGO-DELGADO M, GONZÁLEZ-LÓPEZ E, MUÑOZ-BEAMUD F, et al. Extracellular volume detects amyloidotic cardiomyopathy and correlates with neurological impairment in transthyretin-familial amyloidosis[J]. Rev Esp Cardiol (Engl Ed), 2016, 69(10): 923-930. DOI: 10.1016/j.rec.2016.02.027.
[22]
KARAMITSOS T D, PIECHNIK S K, BANYPERSAD S M, et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis[J]. JACC Cardiovasc Imaging, 2013, 6(4): 488-497. DOI: 10.1016/j.jcmg.2012.11.013.
[23]
LAVALL D, VOSSHAGE N H, GEßNER R, et al. Native T1 mapping for the diagnosis of cardiac amyloidosis in patients with left ventricular hypertrophy[J]. Clin Res Cardiol, 2023, 112(3): 334-342. DOI: 10.1007/s00392-022-02005-2.
[24]
MARTINEZ-NAHARRO A, KOTECHA T, NORRINGTON K, et al. Native T1 and extracellular volume in Transthyretin amyloidosis [J]. JACC Cardiovasc Imaging, 2019, 12(5): 810-9. DOI: 10.1016/j.jcmg.2018.02.006.
[25]
CHENG Z P, LU M J, YIN G, et al. Native T1 mapping for the diagnosis of cardiac amyloidosis: a pilot research[J]. Chin J Radiol, 2016, 50(12): 935-939. DOI: 10.3760/cma.j.issn.1005-1201.2016.12.006.
[26]
JIANG S. Application of 3.0T magnetic resonance T1 mapping technique in differential diagnosis of myocardial amyloidosis and hypertrophic cardiomyopathy[D]. Beijing: Peking Union Medical College, 2017. DOI: 10.3760/cma.j.issn.1005-1201.2016.12.006.
[27]
GERTZ M A. Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment[J]. Am J Hematol, 2020, 95(7): 848-860. DOI: 10.1002/ajh.25819.
[28]
OBI C A, MOSTERTZ W C, GRIFFIN J M, et al. ATTR epidemiology, genetics, and prognostic factors[J]. Methodist Debakey Cardiovasc J, 2022, 18(2): 17-26. DOI: 10.14797/mdcvj.1066.
[29]
FENG C J, LIU W Y, SUN X X, et al. Cardiac MR in differentiating acute viral myocarditis from myocardial involvement in idiopathic inflammatory myopathy[J]. J Pract Radiol, 2022, 38(2): 222-226. DOI: 10.3969/j.issn.1002-1671.2022.02.011.
[30]
WU X Q, FENG Y L, LI C P, et al. The advances in cardiovascular magnetic resonance imaging for light-chain and transthyretin-related amyloidosis[J]. Chin J Magn Reson Imag, 2020, 11(8): 707-711. DOI: 10.12015/issn.1674-8034.2020.08.028.
[31]
ZHAO L, TIAN Z, FANG Q. Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis[J/OL]. BMC Cardiovasc Disord, 2016, 16: 129 [2023-05-29]. https://pubmed.ncbi.nlm.nih.gov/27267362/. DOI: 10.1186/s12872-016-0311-6.
[32]
LI X, PAN C X, LIU W Y, et al. Animal experimental study on evaluation of acute myocardial infarction by T1mapping[J]. J Pract Radiol, 2020, 36(6): 980-983, 1003. DOI: 10.3969/j.issn.1002-1671.2020.06.032.
[33]
MARTINEZ-NAHARRO A, ABDEL-GADIR A, TREIBEL T A, et al. CMR-verified regression of cardiac AL amyloid after chemotherapy[J]. JACC Cardiovasc Imaging, 2018, 11(1): 152-154. DOI: 10.1016/j.jcmg.2017.02.012.
[34]
MANOLIS A S, MANOLIS A A, MANOLIS T A, et al. Cardiac amyloidosis: an underdiagnosed/underappreciated disease[J]. Eur J Intern Med, 2019, 67: 1-13. DOI: 10.1016/j.ejim.2019.07.022.
[35]
PAN J A, KERWIN M J, SALERNO M. Native T1 mapping, extracellular volume mapping, and late gadolinium enhancement in cardiac amyloidosis: a meta-analysis[J]. JACC Cardiovasc Imaging, 2020, 13(6): 1299-1310. DOI: 10.1016/j.jcmg.2020.03.010.

PREV Value of the CMR feature tracking technique in the assessment of the left heart in patients with Parkinson,s disease
NEXT A MRI-Radiomics-based model predicts EGFR mutation status in brain metastases in lung cancer patients
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn